Our company
About CuraCell
CuraCell is a European clinical-stage biotechnology company developing next-generation T-cell therapies for difficult-to-treat solid tumours. Our lead investigational therapy, CC-38, is supported by the proprietary CytoPLY™ T-cell activation and enrichment platform.
Our story
From scientific insight to clinical development
CuraCell was founded with the ambition to advance cell-based immunotherapies for patients with difficult-to-treat solid tumours. Building on tumour-infiltrating lymphocyte biology, scientific collaboration and clinical experience, CuraCell has developed the proprietary CytoPLY™ platform and advanced CC-38 as its lead investigational TIL therapy.
Leadership team
-
Jonas Båtelson
CEO & Co-founder
Read more about Jonas -
Martina Ochel
COO
Read more about Martina -
Lucas Arruda
Chief Scientific Officer
Read more about Lucas -
Torbjörn Ström
Head of Clinical Operations
Read more about Torbjörn -
Per-Henrik Holmqvist
Head of CMC
Read more about Per-Henrik -
Håkan Hallberg
CFO
Read more about Håkan -
Prof. Dr. Thomas Schlegel
General Counsel
Read more about Thomas
Scientific advisory board
-
Prof. Dr. Elke Jäger
-
Prof. Dr. Michael Uhlin
-
Prof. Dr. Ola Winqvist
-
Dr. Thomas Jaecklin
-
Prof. Martin Forster
